Dai Guo-Hu, Zhang Tong, Wu Bo, Jiao Hua-Chen, Liu Yuan-Feng, Song Xian-Bo
Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013 Jun;33(6):795-9.
To explore the effect of Chinese herbs for Shen invigorating and blood activating (CHSIBA) on the number of endothelial progenitor cells (EPCs) in the bone marrow and the peripheral blood and the signaling pathway of bone marrow matrix metalloproteinase 9 (MMP-9) of the myocardial infarction (MI) model rats.
The MI rat model was established by ligation. Thirty successfully modeled rats were randomly divided into the high dose CHSIBA group, the low dose CHSIBA group, and the model group, 10 in each group. Besides, another 10 normal rats were recruited as the blank group. Rats in the high dose CHSIBA group and the low dose CHSIBA group were administered with CHSIBA at 3 g/kg and 1.5 g/kg body weight by gastrogavage (by adding them in 4 mL physiological saline), once daily. Rats in the model group and the blank group were administered with 4 mL physiological saline once daily. The EPCs were collected from the bone marrow and the peripheral blood 4 weeks later. Seven days later the CD34/CD133 phenotype was identified in collected sticking wall cells using flow cytometry. The MMP-9 and water soluble Kit ligand (sKitL) were detected using Western blot. The expressions of vascular endothelial growth factor (VEGF) and stromal cell-derived factor-1alpha (SDF-1alpha) were detected using ELISA.
The CD34/CD133 positive rate and the EPC quantity in the bone marrow and the peripheral blood were higher in the high dose CHSIBA group and the low dose CHSIBA group than in the model group (P < 0.05, P < 0.01). Besides, the expressions of VEGF, SDF-1alpha, MMP-9, and sKitL in the bone marrow and the peripheral blood were also higher in the high dose CHSIBA group and the low dose CHSIBA group than in the model group (P < 0.05, P < 0.01).
CHSIBA could activate MMP-9 signaling pathway, increase its upstream and downstream signal expression levels, and mobilize EPCs in the bone marrow to enter the blood circulation.
探讨补肾活血中药对心肌梗死（MI）模型大鼠骨髓及外周血中内皮祖细胞（EPCs）数量及骨髓基质金属蛋白酶9（MMP-9）信号通路的影响。
采用结扎法建立MI大鼠模型。将30只成功造模的大鼠随机分为高剂量补肾活血中药组、低剂量补肾活血中药组和模型组，每组10只。另外，选取10只正常大鼠作为空白组。高剂量补肾活血中药组和低剂量补肾活血中药组大鼠按3 g/kg和1.5 g/kg体重灌胃给予补肾活血中药（加入4 mL生理盐水中），每日1次。模型组和空白组大鼠每日给予4 mL生理盐水。4周后采集骨髓和外周血中的EPCs。7天后，采用流式细胞术鉴定收集的贴壁细胞中的CD34/CD133表型。采用蛋白质免疫印迹法检测MMP-9和水溶性Kit配体（sKitL）。采用酶联免疫吸附测定法检测血管内皮生长因子（VEGF）和基质细胞衍生因子-1α（SDF-1α）的表达。
高剂量补肾活血中药组和低剂量补肾活血中药组骨髓及外周血中CD34/CD133阳性率和EPC数量均高于模型组（P < 0.05，P < 0.01）。此外，高剂量补肾活血中药组和低剂量补肾活血中药组骨髓及外周血中VEGF、SDF-1α、MMP-9和sKitL的表达也高于模型组（P < 0.05，P < 0.01）。
补肾活血中药可激活MMP-9信号通路，增加其上下游信号表达水平，动员骨髓中的EPCs进入血液循环。
